FierceBiotech11h
OS Therapies' HER2 drug prevented lung cancer from returning in a 3rd of patients
The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...
FierceBiotech12h
Keros, after halting 2 cohorts over fluid buildups around heart, pulls plug on hypertension trial
A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...
FierceBiotech19h
JPM25: GSK’s CSO shares science strategy behind deal-heavy year
And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...
FierceBiotech10h
JPM25: GE HealthCare, UCSF launch research hub for cancer, neurodegenerative disease imaging
GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...
FierceBiotech11h
Neumora's dig into phase 3 depression data disappoints analysts
Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...
FierceBiotech11h
FDA elevates Philips cardiac telemetry recall over unflagged ECG alerts, following 2 deaths
The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...
FierceBiotech17h
JPM25, Day 3: GSK’s liver disease plans, the Biotech CEO Sisterhood, and more
Yesterday, spots of pink could be spotted on the streets of San Francisco, and it wasn’t a coincidence. Members of the ...